Seroatlas · Human Serome Atlas

PLA2G7

Platelet-activating factor acetylhydrolase

Also known as: LDL-PLA2, PAFA_HUMAN, PAFAH

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q13093
Gene
PLA2G7
Ensembl
ENSG00000146070
Chromosome
6
Canonical length
441 aa
Protein class
Candidate cardiovascular disease genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted secreted proteins
Secretome location
Secreted to blood

OverviewNCBI Gene

The protein encoded by this gene is a secreted enzyme that catalyzes the degradation of platelet-activating factor to biologically inactive products. Defects in this gene are a cause of platelet-activating factor acetylhydrolase deficiency. Two transcript variants encoding the same protein have been found for this gene.[provided by RefSeq, Dec 2009]

Canonical amino-acid sequenceUniProt

441 residues, UniProt reviewed canonical sequence.

>Q13093|PLA2G7
     1  MVPPKLHVLF CLCGCLAVVY PFDWQYINPV AHMKSSAWVN KIQVLMAAAS FGQTKIPRGN
    61  GPYSVGCTDL MFDHTNKGTF LRLYYPSQDN DRLDTLWIPN KEYFWGLSKF LGTHWLMGNI
   121  LRLLFGSMTT PANWNSPLRP GEKYPLVVFS HGLGAFRTLY SAIGIDLASH GFIVAAVEHR
   181  DRSASATYYF KDQSAAEIGD KSWLYLRTLK QEEETHIRNE QVRQRAKECS QALSLILDID
   241  HGKPVKNALD LKFDMEQLKD SIDREKIAVI GHSFGGATVI QTLSEDQRFR CGIALDAWMF
   301  PLGDEVYSRI PQPLFFINSE YFQYPANIIK MKKCYSPDKE RKMITIRGSV HQNFADFTFA
   361  TGKIIGHMLK LKGDIDSNVA IDLSNKASLA FLQKHLGLHK DFDQWDCLIE GDDENLIPGT
   421  NINTTNQHIM LQNSSGIEKY N

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PLA2G7 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Secreted
Secreted
Yes
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.26
Highest tissue expression
26 nTPM

Expression across tissuesHPA

Tissue

  • spleen: 26 nTPM
  • lymph node: 25 nTPM
  • placenta: 22 nTPM
  • appendix: 22 nTPM
  • parathyroid gland: 20 nTPM
  • thyroid gland: 19 nTPM

Single-cell type

  • hofbauer cells: 504 nCPM
  • decidual stromal cells: 124 nCPM
  • macrophages: 87 nCPM
  • kupffer cells: 83 nCPM
  • prostatic glandular cells: 72 nCPM
  • retinal pigment epithelial cells: 55 nCPM

Immune cell

  • classical monocyte: 43 nTPM
  • myeloid DC: 14 nTPM
  • total PBMC: 12 nTPM
  • intermediate monocyte: 9.2 nTPM
  • neutrophil: 0.5 nTPM
  • non-classical monocyte: 0.4 nTPM

Brain region

  • thalamus: 21 nTPM
  • white matter: 18 nTPM
  • pons: 10 nTPM
  • medulla oblongata: 9.8 nTPM
  • basal ganglia: 8.9 nTPM
  • spinal cord: 7.5 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about PLA2G7.

Disease | AllUniProt

Conditions PLA2G7 is implicated in, by any mechanism.

  • Platelet-activating factor acetylhydrolase deficiency (PAFAD) MIM:614278

Disease | GeneticClinVar

3 pathogenic / likely-pathogenic of 118 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Platelet-activating factor acetylhydrolase deficiency

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.71
gnomAD pLI
0
gnomAD missense Z
-1.05
DepMap mean gene effect
0
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PLA2G7 as an antibody target. Whether an autoantibody or antibody against PLA2G7 could matter depends on whether native PLA2G7 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PLA2G7 is annotated as secreted, so native PLA2G7 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label PLA2G7 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/PLA2G7. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...